Evidence map›Paper›PMID 30693698›Full record

ReviewZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2018

[Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].

Rui Hao, Lide Su, Yiming Shao, Na Bu, Liya Ma, Hua Naranmandura

Open access · greenAbstract readReview
In one paragraph

Review in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rui HaoDepartment of Pharmacology, Inner Mongolia Medical University, Hohhot 010000, China.
Lide SuDepartment of Pharmacology, Inner Mongolia Medical University, Hohhot 010000, China.
Yiming ShaoDepartment of Pharmacology, Inner Mongolia Medical University, Hohhot 010000, China.
Na BuDepartment of Pharmacy, Woman's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Liya MaDepartment of Hematology, the First Affiliate Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Hua NaranmanduraDepartment of Pharmacology, Inner Mongolia Medical University, Hohhot 010000, China.
Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Promyelocytic leukemia (PML) protein, a tumor suppressor, plays an important role in patients with acute promyelocytic leukemia (APL) receiving arsenic trioxide (As

Indexed as

Arsenic TrioxideLeukemia, Promyelocytic, AcutePromyelocytic Leukemia ProteinAntineoplastic AgentsDrug Resistance, NeoplasmHumansMutationOncogene Proteins, FusionAntineoplastic AgentsArsenic TrioxideOncogene Proteins, FusionPromyelocytic Leukemia Protein

Identifiers

PMID30693698
PMCPMC10393665
OpenAlexW2992110650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.